CD3/CD19 bispecific antibody (Beijng Immunoah Pharma Tech)

N/A

Report date: 2026/03/19 17:14:51

Base Information

Drug NameCD3/CD19 bispecific antibody (Beijng Immunoah Pharma Tech)

Drug Alias NameCD3/CD19 Fab (Beijng Immunoah Pharma Tech)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Anti-CD19

TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD19

Therapy Area/IndicationsHematoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesBeijng Immunoah Pharma Tech Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesBeijng Immunoah Pharma Tech Co Ltd

Inactive CompaniesN/A

Active IndicationsHematoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A